Tepotinib has been shown to overcome the acquired resistance to first generation EGFR TKIs in NSCLC with T790M mutation, displaying complete regression in xenograft studies when combined with rocelitinib, a third generation EGFR TKI that targets the T790M mutation [46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.